Buradasınız

Akut viral hepatit C

Acute viral hepatitis C

Journal Name:

Publication Year:

DOI: 
doi:10.2399/tahd.08.089

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In the following review, viral hepatitis C disease which is a heavy burden for the public health, is discussed.
Abstract (Original Language): 
Bu derlemede taşıyıcılık ve komplikasyonları nedeniyle toplum sağlığı yönünden çok önemli bir yer işgal eden viral hepatit C hastalığı tüm yönleri ile ele alınmaya çalışılmıştır.

REFERENCES

References: 

1. Agboatwalla
M
, Isomura S, Miyake K, Yamashita T, Morishita T, Akram DS. Hepatitis A, B and C seroprevalence in Pakistan. Indian J Pediatr 1994; 61: 545-9.
2.
Dikic
i B. Diyarbakır İl Merkezinde ilköğretim Okullarında HCV Prevalansı. Uzmanlık Tezi, Diyarbakır, 1999.
3.
Dikic
i B, Boşnak M, Kara İH, Doğru Ö, Haspolat K. Diyarbakır il merkezinde çocuklarda anti-HCV prevalansı. Hacettepe Çocuk Sağlığı ve Hastalıkları Dergisi 2002; 45: 36-40.
4. Aggarwal V, Prakash C, Yadav S, Chattopadhya D. Prevalence of trans¬fusion associated infections in multitransfused children in relation to mandatory screening of HIV in donated blood. Southeast Asian J Trop Med Public Health 1997; 28: 699-706.
5. Akahane Y, Aikawa T, Sugai Y, Tsuda F, Okamoto H, Mishiro S. Transmission of HCV between spouses. Lancet 1992; 339: 1059-60.
6. Choo QL, Kuo G, Weiner A J, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B hepatitis genome. Science 1989; 244: 359-62.
7. Bukh J. Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 41-63.
8. Rehermann B. Immunopathogenesis of hepatitis C. In: Liang TJ, moder¬ator. Pathogenesis, natural history, treatment, and prevention of hepatitis
C. Ann Intern Med2000;132:296-305
9. Çullu F. Çocukluk Çağında A, B, C, Hepatitleri. Viral Hepatit Kitabı-
2002. Editörler: Balık İ, Tekeli E. Ankara, VHSD, 2002.
10. Mıstık R, Balık I. Türkiyede Viral Hepatitlerin Epidemiyolojisi: Bir Metaanaliz. Kılıçturgay K (Editör). Viral Hepatit 1998. Birinci Baskı. İstanbul, Viral Hepatitle Savaşım Derneği, 1998.
11. Mitsui T, Iwano K, Masuko K ve ark. Hepatitis C virus infection in
med
¬ical personnel after needlestick accident. Hepatology 1992; 16: 1109-14.
12. Kara
İH
, Aydın B, Kızıl A ve Saka G. Hemşirelerde HBV ve HCV Seroprevalansı ve İğne Yaralanmaları ve Diğer Risk Faktörlerinin Değerlendirilmesi. Sendrom 2002; 14: 139-42.
13. Suzuki K, Mizokami M, Lau S ve ark. Confirmation of hepatitis C virus transmission through needlestick accident by moleculer evolutionary analysis. J Infect Dis 1994; 170: 1575-8.
14. Martinson FE, Weigle KA, Mushahwar IK, Weber DJ, Royce R, Lemon SM. Seroepidemiological survey of hepatitis B and C virus infections in Ghanaian children. J Med Virol 1996; 48: 278-83.
15. Montes Martinez I, Agulla Budino A. Prevalence of antibodies against hepatitis A, B, C and E viruses in the rural child population in Northern Extremadura. An Esp Pediatr 1996; 45: 133-6.
20. Martins RM, Porto SO, Vanderborght BO ve ark. Short report: preva¬lence of hepatitis C viral antibody among Brazilian children, adolescents, and street youths. Am J Trop Med Hyg1995; 53: 654-5.
21. Yousefi AR, Arslantürk A, Bingöl N, Akdenizli MA, Ommety R. Non dönor populasyonda anti HCV seroprevalansı. IX Türk klinik mikrobiy¬oloji ve enfeksiyon hastalıkları Kongre Kitabı, Antalya, 1999; s. 186.
22. Durupınar B, Saniç A, Günaydın M ve ark. Prevalence of Hepatitis C Virus Antibodies In Different Patient Groups. Ondokuz Mayıs Üniversitesi Tıp Fakültesi Dergisi 1992; 9: 251-3.
23.
Taşyara
n MA, Akdağ R, Akyüz M ve ark. Erzurum Bölgesi Çocuklarında Parenteral Bulaşan Hepatit Viruslarının Seroprevalansı Klimik Dergisi
1994; 7: 76-8.
24.
Uça
r B, Akgün N, Akgün Y ve ark. Eskişehir yöresinde çocuklarda hepatit C seroepidemiyolojisi. Çocuk Sağlığı ve Hastalıkları Dergisi 1998; 41: 233¬40.
25.
Atabe
k ME, Ural O, Çoban A. Konya'da çocuklarda hepatit A, B, C sero-prevalansı. Çocuk Sağlığı ve Hastalıkları Dergisi 2001; 44: 66-70.
26. Lever AM, Webster AD, Brown D, Thomas HC. Non A, non B hepati¬tis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984; 2; 1062-4.
27. Jonas MM, Zilleruelo G, LaRue SI , Abitbol C, Strauss J, Lu Y. Hepatitis C infection in pediatric dialysis population. Pediatrics 1992; 89: 707-9.
28. Bak M, Aksu N, Kabasakal C, Cura A. Hemodializ
hastalarınd
a hepatit B ve hepatit C enfeksiyonu ve hepatit aşı uygulaması. İstanbul Çocuk Kliniği
Dergisi 1993; 4: 229-32.
29.
Kar
a IH, Yilmaz ME, Sari Y, Düzen S, Usul Y, Işikoğlu B. Seroprevalence and Risk Factors of HCV in Dialysis Patients in a University Hemodialysis Center of Southeast Anatolia of Turkey. Dialysis & Transplantation 2001; 11: 748-55.
30. Contreras M, Barbara JA, Anderson CC ve ark. Low incidence of non- A, non-B posttransfusion hepatitis in London confirmed by hepatitis C virus serology. Lancet 1991; 337: 753-7.
31. Donahue JG, Munoz A, Ness PM ve ark. The declining risk of post transfusion hepatitis C virus infection. NEng J Med 1992; 327: 369-73.
32. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody on incidence of post- transfusion
hepatitis. Lancet 1991; 338: 1040.
33. Esteban JI, Gonzoles A, Hernandez JM ve ark. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Eng J
Med1990; 323: 1107-10.
34. Wang TH, Wang JT, Lin JT ve ark. A prospective study of post transfu¬sion hepatitis in Taiwan. J Hepatol 1991; 13: 38-43.
35. Alter MJ, Hadler SC, Judson FN ve ark. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus
infection. JAMA1990; 264: 2231-5.
36. Çakaloğlu Y, Ökten A, Kaymakoğlu S et al. Prevalence of antibody to hepatitis C virus in cryptogenic, hepatitis B related and alcoholic chronic liver disease and in blood donors in Türkiye. Turk J Med Biol 1992; 3: 53¬7.
37. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351-5.
38. Hallam NF, Fletcher MI, Read SJ, Majid AM, Kurtz JB, Rizza CR. Low
risk of sexual transmission of hepatitis C virus. J Med Virol1993; 40: 251¬3.
39. Terada S, Kawanishi K, Katayama K. Minimal hepatitis C infectivity in
semen. Ann Intern Med1992; 117: 171-172.
40. Menendez SR, Garcia M.R, Sanchez San Roman F ve ark. Intrafamilial spread of hepatitis C virus. Infection 1991; 19: 431-3.
e 3
Türkiye Aile Hekimliği Dergisi |
Turkish Journal of Family Practice | Cilt 12 | Sayı 2 | 2008
93
41. Mondello P, Patti S, Vitale M.G, D'Accordo AM, Spano C. Anti -HCV
antibodies in ho-usehold contacts of patients with cirrhosis of liver-pre¬liminary results. Infection 1992; 20: 51-2.
42. Tanaka E, Kiyosawa K, Sodeyama T ve ark. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: a comparison with adult blood donors. Am J Trop Med Hyg 1992; 46: 460-4.
43.
Dikic
i B, Yılmaz ME, Boşnak M, Sarı Y, Kara İH. Anti HCV pozitif hemodiyaliz hastalarının çocuklarında anti-HCV seroprevalansı. Viral
Hepatit Dergisi 2001; 3: 405-7.
44. Ohto H, Terazawa S, Sasaki N ve ark. Transmission of hepatitis C vi-rus
from mothers to infants. N Eng J Med1994; 330: 744-50.
45. Manzini P, Saracco G, Cerchier A ve ark. Human immunodefıciency virus infection as risk factor for mother-to-child hepatitis C virus trans¬mission; persistence of anti-hepatitis C virus in children is as-sociated with the mother's anti-hepatitis C virus immunoblotting pattern.
Hepatology1995; 21: 328-32.
46. Allander T, Gruber A, Naghavi M ve ark. Frequent patient to-patent transmission of hepatitis C virus in a hematology ward. Lancet 1995; 345:
601-7.
47. Bortolotti F, Vajro P, Barbera C ve ark. Hepatitis C in childhood: epi-demiological and clinical aspects. Bone Marrow Transplantation 1993; 12:
21-3.
48. Ceci O, Margiotta M, Marello F ve ark. High rate of spontaneous viral clearance in a cohort of vertically infected hepatitis C virus infants: what lies behind? J Hepatol 2001; 35: 687-8.
49. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Sem Liver Dis1995; 15: 101-9.
50. Clifford BD, Donahue D, Smith L ve ark. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology
1995; 21: 613-9.
51. Mackie FD, Peakman M, Yun M ve ark. Primary and secondary liver/kid¬ney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology 1994; 106: 1672-5.
52. Bortolotti F, Vajro P, Balli F ve ark. Non organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25: 614-20.
53. Pillot J, Dubreuil P. Are blotting tests (Riba, western-blot.. ) still useful as markers of hepatitis C vinıs infection? Hepatol1995; 23: 103-5.
54. Van Doorn U. Molecular biology of the hepatitis C virus. J Med Virol
1994; 43: 345-56.
55. Simmonds P. Variability of hepatitis C virus. Hepatology1995; 21: 570-83.
56. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F ve ark. Relationship between hepatitis C virus genotypes and sources of infection in patients
with chronic hepatitis C. J Infect Dis1995; 171:1607-10.
57. Iorio R, Fariello I, Guida S et al. Alpha lymphoblastoid interferon thera¬py in 12 children with chronic hepatitis C. Hepatology1993; 18: 237.
58. Sinha M, Das A. Cost effectiveness analysis of different strategies of man¬agement of chronic hepatitis C infection in children. Pediatr Infect Dis J
2000; 19: 23-30.
59. Bortolotti F. Treatment of chronic hepatitis C.in children. J Hepatol
1999; 31: 201-4.
60. Ruiz-Moreno M, Leal Orozco A, Millan A. Hepatitis C virus infection in
children. J Hepatol1999; 31:124-129.
61. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 52-8.
62. Lackner H, Moser A, Deutsch J ve ark. Interferon alfa and ribavirin in treating children and young adults with chronic hepatitis C after malig¬nancy. Pediatrics2000: 106: 53.
63. Gonzalez A, Esteban JI, Medoz P ve ark. Efficacy of screening donor for antibodies to the hepatitis C virus to prevent transfusion-associated hep¬atitis: final report of a prospective trial. Hepatology1995; 22: 439-45.
64. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and cytomegalovirus among health care personnel at risk for blood exposure: final report from a lon¬gitudinal study. J Infect Dis1994; 170: 1410-7.
65. Donnelly JJ, Friedman A, Martinez D ve ark. Preclinical efficacy of a pro¬totype DNA vaccine: Enhanced protection against antigenic drift in
influenza virus. Nat Med1995; 1: 583-7.

Thank you for copying data from http://www.arastirmax.com